Effects of Empagliflozin Treatment on Cardiac Biomarkers in Adults With Metabolically Healthy Obesity: Results From a Randomized, Placebo-Controlled Clinical Trial

Mayo Clin Proc. 2021 Aug;96(8):2282-2284. doi: 10.1016/j.mayocp.2021.06.012.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Benzhydryl Compounds / therapeutic use*
  • Biomarkers / blood
  • Female
  • Glucosides / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Myocardial Ischemia / blood*
  • Myocardial Ischemia / etiology
  • Obesity, Metabolically Benign / blood
  • Obesity, Metabolically Benign / complications
  • Obesity, Metabolically Benign / drug therapy*
  • Randomized Controlled Trials as Topic*
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Troponin / blood*

Substances

  • Benzhydryl Compounds
  • Biomarkers
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • Troponin
  • empagliflozin